Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ponicidin is a diterpenoid compound isolated from the plant Rabdosia rubescens (often known as Dong Ling Cao). It has demonstrated **antitumor, anti-inflammatory, and immunoregulatory** activities in preclinical studies. Mechanistically, ponicidin is proposed to induce apoptosis in cancer cells through mitochondrial pathways, inhibit inflammatory cytokine production, and modulate immune responses. Its primary research focus has been on oncology (solid tumors including leukemia, gastric, colon, and lung cancers), and inflammatory or autoimmune diseases. Ponicidin is not approved by regulatory agencies as a pharmaceutical drug and is generally studied in vitro and in animal models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ponicidin.